CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
CPG 7909 given alone to patients with renal cell cancer after their nephrectomy. CPG 7909 is
as a subcutaneous injection once per week for up to 24 weeks. Up to 40 patients will be
included in the study.